SANDERLING V LTD PARTNERSHIP

Form 3 April 10, 2013

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

HIP OF Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement CHIMERIX INC [CMRX] **Â** Sanderling Venture Partners (Month/Day/Year) 04/10/2013 V. LP (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 400 SOUTH EL CAMINO (Check all applicable) REAL. SUITE 1200 (Street) 6. Individual or Joint/Group __X__ 10% Owner Director Officer Other Filing(Check Applicable Line) (give title below) (specify below) Form filed by One Reporting Person SAN MATEO. CAÂ 94402 X Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security 2. Amount of Securities 3. 4. Nature of Indirect Beneficial Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5) Common Stock 112,674 Ι SEE FOOTNOTE (1) Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

information contained in this form are not required to respond unless the form displays a

currently valid OMB control number.

3. Title and Amount of 6. Nature of Indirect 1. Title of Derivative Security 2. Date Exercisable and 4. 5. **Expiration Date** Securities Underlying Conversion Ownership Beneficial Ownership (Instr. 4) (Month/Day/Year) **Derivative Security** or Exercise Form of (Instr. 5) (Instr. 4) Price of Derivative Derivative Security:

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Series A Preferred Stock	(2)	(2)	Common Stock	183,096	\$ (2)	I	SEE FOOTNOTE (1)
Series B Preferred Stock	(3)	(3)	Common Stock	474,330	\$ <u>(3)</u>	I	SEE FOOTNOTE
Series B-1 Preferred Stock	(4)	(4)	Common Stock	469,480	\$ <u>(4)</u>	I	SEE FOOTNOTE (1)
Series C Preferred Stock	(5)	(5)	Common Stock	695,496	\$ <u>(5)</u>	I	SEE FOOTNOTE
Series D Preferred Stock	(6)	(6)	Common Stock	771,372	\$ <u>(6)</u>	I	SEE FOOTNOTE
Series E Preferred Stock	(7)	(7)	Common Stock	619,852	\$ <u>(7)</u>	I	SEE FOOTNOTE
Series F Preferred Stock	(8)	(8)	Common Stock	792,037	\$ <u>(8)</u>	I	SEE FOOTNOTE
Warrants	(9)	02/11/2018	Common Stock	198,008	\$ 7.26	I	SEE FOOTNOTE

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Sanderling Venture Partners V, LP 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO, CA 94402	Â	ÂX	Â	Â	
SANDERLING V BIOMEDICAL LP Â	Â	ÂX	Â	Â	
SANDERLING V LTD PARTNERSHIP 400 SOUTH EL CAMINO REAL STE 1200 SAN MATEO, CA 94402-1708	Â	ÂX	Â	Â	
SANDERLING V BETEILIGUNGS GMBH & CO KG 400 SOUTH EL CAMINO REAL STE 1200 SAN MATEO, CA 94402-1708	Â	ÂX	Â	Â	
SANDERLING VENTURES MANAGEMENT V 400 SOUTH EL CAMINO REAL STE 1200 SAN MATEO, CA 94402-1708	Â	ÂX	Â	Â	
	Â	ÂΧ	Â	Â	

Reporting Owners 2

Â

Â

SANDERLING V BIOMEDICAL CO INVESTMENT FUND LP
400 SOUTH EL CAMINO REAL
STE 1200
SAN MATEO, CAÂ 94402-1708
Sanderling Venture Partners V Co Investment Fund, LP
400 SOUTH EL CAMINO REAL
SUITE 1200
SAN MATEO, CAÂ 94402
Sanderling V Strategic Exit Fund LP

Sanderling V Strategic Exit Fund LP

400 SOUTH EL CAMINO REAL
SUITE 1200
SAN MATEO, CAÂ 94402
 Â X Â

Sanderling Venture Partners VI Co Investment Fund LP

400 SOUTH EL CAMINO REAL STE 1200 Â Â X Â Â

SAN MATEO, CAÂ 94402-1708

Sanderling VI Beteiligungs GmbH & Co KG 400 SOUTH EL CAMINO REAL, SUITE 1200 Â Â X Â Â SAN MATEO, CAÂ 94402

Signatures

See Signatures Included in Exhibit 99.2

04/10/2013

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) See attached Exhibit 99.1.
- The Series A Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of Series A Preferred Stock, for no additional consideration.
- The Series B Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of Series B Preferred Stock, for no additional consideration.
- The Series B-1 Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of Series B-1 Preferred Stock, for no additional consideration.
- The Series C Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of Series C Preferred Stock, for no additional consideration.
- The Series D Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of Series D Preferred Stock, for no additional consideration.
- The Series E Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of Series E Preferred Stock, for no additional consideration.
- (8) The Series F Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of

Signatures 3

Series F Preferred Stock, for no additional consideration.

(9) The warrants are immediately exercisable.

Â

Remarks:

Form 3 filing 1 of 2. See Form 3 filing 2 of 2 for additional members of this joint filing.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.